Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01138345 · ClinicalTrials.gov registry record
Biomarkers in Blood Samples From Older Breast Cancer Survivors
A clinical trial of Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 246
- Enrollment target
- 1
- Study location
NCT01138345: Completed study of Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT01138345 is a study of Breast Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 246 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01138345, a study of Breast Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in blood samples from older women with stage I, stage II, or stage III breast cancer who have finished primary therapy or breast cancer survivors.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- OTHER questionnaire administration
- GENETIC reverse transcriptase-polymerase chain reaction
Study Locations (1)
North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-02 |
What the finished NCT01138345 record still lists
NCT01138345 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT01138345 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01138345 about?
NCT01138345 is a clinical study titled "Biomarkers in Blood Samples From Older Breast Cancer Survivors". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in blood samp...
What is the current status of trial NCT01138345?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2010-01. Estimated completion is 2014-02.
What conditions does trial NCT01138345 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01138345?
The interventions under investigation include: gene expression analysis (GENETIC), laboratory biomarker analysis (OTHER), medical chart review (OTHER), questionnaire administration (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT01138345?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01138345 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01138345's enrollment target sits among peer trials
246 332nd of 1224 higher than 893 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia